The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL).
 
Samuel Cass
No Relationships to Disclose
 
Joshua Tobin
No Relationships to Disclose
 
Yongwoo David Seo
No Relationships to Disclose
 
Georgina Gener-Ricos
No Relationships to Disclose
 
Emily Zhi-Yun Keung
No Relationships to Disclose
 
Elizabeth M. Burton
No Relationships to Disclose
 
Danielle M. Walsh
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Paul Joseph Hampel
No Relationships to Disclose
 
Jennifer Ann Wargo
Stock and Other Ownership Interests - Micronoma
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; DAVA Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - DAVA Oncology; Genentech; Illumina; Novartis; PER/CURE Media Group; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; DAVA Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Alessandra Ferrajoli
Consulting or Advisory Role - AstraZeneca; Giants of Cancer Care; Janssen Oncology
Patents, Royalties, Other Intellectual Property - Acerta Pharma; BeiGene; Celgene